Tumour invasion and metastasis: challenges facing drug discovery

Area of Science:

• Oncology
• Pharmacology
• Cancer Metastasis Research

Background:

• Previous anti-invasive therapies targeting matrix metalloproteases showed limited success.
• New targeted agents and monoclonal antibodies offer potential for anti-metastasis treatment.
• Demonstrating clinical efficacy of novel anti-invasive agents remains a challenge.

Purpose of the Study:

• To highlight the need for improved drug discovery and clinical evaluation methods for anti-invasive cancer therapies.
• To address the challenges in demonstrating the effect of novel agents on tumor metastasis.
• To guide the development of clinically predictive models for anti-metastasis drug candidates.

Main Methods:

• Review of past and current anti-invasive therapy approaches.
• Analysis of challenges in clinical translation of targeted anti-metastasis agents.
• Discussion of the role of monoclonal antibodies in cancer therapy.

Main Results:

• Matrix metalloprotease inhibitors have not fulfilled the promise of anti-invasive therapy.
• A clear pathway to demonstrate the anti-metastatic effect of new agents is lacking.
• Advances in monoclonal antibodies necessitate better preclinical and clinical assessment strategies.

Conclusions:

• More clinically predictive drug discovery cascades are needed for anti-invasive agents.
• New approaches are essential to validate early clinical responses and prevent failures.
• Improved methodologies will enhance the development of effective anti-metastasis treatments.